BioSpace News Archive

Lone Star Bio

Lantern Pharma’s A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024

Lantern Pharma’s A.I. Platform, RADR ® Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines.

March 4, 2024
·
10 min read
Business

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024

IPA today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third fiscal year 2024, on Thursday, March 14, 2024, at 10:30 am Eastern Time.

March 4, 2024
·
2 min read
Genetown

Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development

Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development.

March 4, 2024
·
4 min read
Pharm Country

UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024

UroGen Pharma Ltd. today announced that it will report fourth quarter and full-year 2023 financial results on Thursday, March 14, 2024, prior to the open of the stock market.

March 4, 2024
·
1 min read
Drug Development

Invitation to Participate in STOP-PC Clinical Trial

Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial which is now open for recruitment.

March 4, 2024
·
6 min read
Drug Development

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Vaxcyte, Inc. today announced the completion of enrollment in its Phase 2 study evaluating VAX-24, a broad-spectrum, carrier-sparing 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants.

March 4, 2024
·
10 min read
Drug Development

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

GRI Bio, Inc. today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the UK.

March 4, 2024
·
7 min read
Biotech Bay

Sofwave Medical to Present Pure Impact™ Strength and Muscle Toning Module’s First U.S. Industry Reveal at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Sofwave Medical Ltd is excited to announce its participation at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

March 4, 2024
·
1 min read
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024 at 2:00 p.m. ET in Miami, Florida.

March 4, 2024
·
3 min read
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease

Cyprium Therapeutics, Inc. today announced that the National Institute of Neurological Disorders and Stroke (“NINDS”) of the National Institutes of Health (“NIH”) has awarded a three-year grant totaling approximately $4.1 million to the Research Institute at Nationwide Children’s Hospital.

March 4, 2024
·
11 min read